Studi scientifici principali
- OLYSIO®. Riassunto delle Caratteristiche del Prodotto
- Manns M. et al. “Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial” Lancet 2014; 384 (9941): 414-26
- Jacobson I.M. et al. “Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial” Lancet 2014; 384 (9941): 403-13.
- Foster G.R. et al. “Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in treatment naïve european patients in the QUEST-1 and QUEST-2 phase III trials” Journal of Hepatology 2014; 60: S361-S522; P1127.
- Forns X. et al. “Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial” Gastroenterology 2014; 146 (7): 1669-1679.
- Forns X. et al. “Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in european patients who relapsed after previous interferon-based therapy: the PROMISE trial” Journal of Hepatology 2014; 60: S1–S22; abstract O13.
- Lawitz E. et al. “Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naïve patients: the COSMOS randomized study” The Lancet 2014; 384 (9956): 1756-1765.
- AASLD HCV TARGET
